SCHEMBL2011767

SCHEMBL2011767

O=C(CN1C(=O)Cc2cc(Cl)ccc21)NCCc1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 1/20 0.52
TP53 P04637 1/20 0.49
HPGD P15428 2/20 0.48
GAA P10253 1/20 0.48
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GPR139 Q6DWJ6 1/20 0.46
CNR1 P21554 2/20 0.45
HTT P42858 1/20 0.44
OXTR P30559 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PLAAT3 P53816 1/20 0.43
PLAAT5 Q96KN8 1/20 0.43
PLAAT2 Q9NWW9 1/20 0.43
PLAAT4 Q9UL19 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL659925 0.82 KDM4E (0.47) SMN1; SMN2ALDH1A1KDM4EMAPTLMNA
SCHEMBL662079 0.81 TP53 (0.51) ALDH1A1KDM4EMAPTTP53LMNA
SCHEMBL662248 0.81 KMT2A (0.55) ALDH1A1MAPTTP53HPGDGAA
SCHEMBL27633476 0.81 TP53 (0.46) SMN1; SMN2ALDH1A1KDM4EMAPTTP53
SCHEMBL30361168 0.80 MAPT (0.54) SMN1; SMN2ALDH1A1KDM4EMAPTGAA
SCHEMBL662880 0.80 MAPT (0.54) SMN1; SMN2ALDH1A1KDM4EMAPTGAA
SCHEMBL2853159 0.78 KDM4E (0.43) SMN1; SMN2ALDH1A1KDM4EMAPTTP53
SCHEMBL663113 0.78 NPC1 (0.57) SMN1; SMN2ALDH1A1MAPTTP53LMNA
SCHEMBL660969 0.77 KDM4E (0.45) SMN1; SMN2ALDH1A1KDM4EMAPTTP53
SCHEMBL29868397 0.77 PKM (0.48) ALDH1A1KDM4EMAPTTP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP claimed
CN-100364973-C Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2008-01-30 CN claimed
CN-1768036-A Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2006-05-03 CN claimed
CN-103476255-A Methods and compositions for improving cognitive function UNIV JOHNS HOPKINS 2013-12-25 CN disclosed
CN-102905532-A Methods and compositions for improving cognitive function UNIV JOHNS HOPKINS 2013-01-30 CN disclosed
CN-102227217-A Methods and compositions for improving cognitive function UNIV JOHNS HOPKINS 2011-10-26 CN disclosed
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-09-01 US disclosed
US-7964593-B2 Indolone-acetamide derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2011-06-21 US disclosed
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP disclosed
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2010-03-18 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
CN-100364973-C Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2008-01-30 CN disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
CN-1768036-A Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2006-05-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses AANAT, TPH2, CYP1A2 SMN1; SMN2 3260/4885ALDH1A1 308/4885KDM4E 1236/4885
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE SMN1; SMN2 73/4885ALDH1A1 2614/4885KDM4E 3495/4885
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 SMN1; SMN2 3260/4885ALDH1A1 308/4885KDM4E 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.